Northwest Biotherapeutics (NWBO) is a biotechnology company specializing in personalized immune therapies for cancer. The company develops innovative treatments using its proprietary DCVax® platform technology, which mobilizes a patient’s immune system to target and attack cancer. NWBO focuses on creating therapies for both operable and inoperable solid tumors.
- DCVax®-L - Treats solid tumor cancers where the tumor can be surgically removed. It completed a Phase III clinical trial for glioblastoma (GBM) and is under regulatory review for commercial approval in the U.K..
- DCVax®-Direct - Targets inoperable solid tumors by injecting activated dendritic cells directly into the tumor for antigen loading in situ. Preparations for Phase II trials are ongoing.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Alton L. Boynton ExecutiveBoard | Secretary | Dr. Alton L. Boynton co-founded NWBO in 1998 and has served as Chief Scientific Officer since inception. He held the CEO role from June 2007 to June 2011 and is currently the Secretary (since May 2024) as well as a Class I Director. | ||
Linda F. Powers ExecutiveBoard | President and Chief Executive Officer | Boards of several private biotechnology companies | Linda F. Powers has served as the President and Chief Executive Officer of NWBO since June 8, 2011 and is also the Chairperson of the Board since May 17, 2007, as well as the Chief Financial and Accounting Officer since June 8, 2020. She has a strong background in corporate finance and biotechnology with extensive leadership experience. | View Report → |
Leslie J. Goldman Executive | Senior Vice President and General Counsel | Leslie J. Goldman has served as the Senior Vice President and General Counsel at NWBO since June 2011. He brings decades of legal and investor relations experience from previous roles at law firms and as an advisor. | ||
Marnix L. Bosch Executive | Chief Technical Officer | Dr. Marnix L. Bosch joined NWBO in 2000 and currently serves as the Chief Technical Officer, playing a key role in regulatory applications and the development of manufacturing processes. | ||
Dr. Navid Malik Board | Director (Class III Director) | Head of Research and Executive Director at The Life Sciences Division, UK Investment Bank (Since 2018) | Dr. Navid Malik has been serving as a Director on NWBO’s Board since April 2012 and participates in key committees including Audit, Compensation, and Conflicts. | |
J. Cofer Black Board | Class I Director | J. Cofer Black has served as NWBO’s Class I Director since January 2016 and previously held leadership roles such as Vice President for Global Operations at Blackbird Raytheon Technologies and Vice Chairman of Blackwater Worldwide. | ||
Pat Sarma Board | Class II Director | Pat Sarma has been serving as a Class II Director at NWBO since March 2024 and is actively involved in the Audit, Compensation, and Conflicts Committees. With a strong background in technology and venture capital, he brings extensive experience from his roles at AMI and as a venture investor. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Juno | Actively involved in the research and development of immune therapies or cell-based therapies for cancer. |
Kite | Actively involved in the research and development of immune therapies or cell-based therapies for cancer. |
Sotio | Actively involved in the research and development of immune therapies or cell-based therapies for cancer. |
AiVita | Actively involved in the research and development of immune therapies or cell-based therapies for cancer. |
Mendus | Actively involved in the research and development of immune therapies or cell-based therapies for cancer. |
Actively involved in the research and development of immune therapies or cell-based therapies for cancer. | |
BMS | Rapidly developing checkpoint inhibitor drugs to 'take the brakes off' patients' immune responses to cancer. |
Rapidly developing checkpoint inhibitor drugs to 'take the brakes off' patients' immune responses to cancer. | |
Rapidly developing checkpoint inhibitor drugs to 'take the brakes off' patients' immune responses to cancer. | |
Rapidly developing checkpoint inhibitor drugs to 'take the brakes off' patients' immune responses to cancer. | |
Roche | Rapidly developing checkpoint inhibitor drugs to 'take the brakes off' patients' immune responses to cancer. |
Developed the Optune electro-therapy device, which is used for the treatment of brain cancer. | |
MagForce Nano Technologies AG | Competes in the development of alternative therapies to treat cancer, including medical devices. |
Eisai Co. Ltd. | Produces Gliadel®, a drug used for the treatment of brain cancer. |
Produces Temodar®, a drug used for the treatment of brain cancer. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Flaskworks, LLC | 2020 | Northwest Biotherapeutics completed the acquisition of Flaskworks, LLC on August 28, 2020 for approximately $4.33 million, structured with a cash payment and milestone-based stock and contingent payments. The deal strategically acquired Flaskworks’ intellectual property, technical team, and a license from Northeastern University to automate and scale the manufacturing of DCVax cell therapy products. |
No recent press releases or 8-K filings found for NWBO.